$7.84
1.88% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$7.84
-0.40 4.85% 1M
-1.26 13.85% 6M
-1.14 12.69% YTD
+2.46 45.72% 1Y
-4.09 34.28% 3Y
-7.91 50.22% 5Y
+4.32 122.73% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.15 1.88%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Market capitalization $1.06b
Enterprise Value $817.97m
P/E (TTM) P/E ratio 28.00
EV/FCF (TTM) EV/FCF 12.78
EV/Sales (TTM) EV/Sales 3.31
P/S ratio (TTM) P/S ratio 4.28
P/B ratio (TTM) P/B ratio 3.08
Revenue growth (TTM) Revenue growth 29.20%
Revenue (TTM) Revenue $247.30m
EBIT (operating result TTM) EBIT $48.37m
Free Cash Flow (TTM) Free Cash Flow $64.00m
Cash position $312.59m
EPS (TTM) EPS $0.28
P/E forward 16.33
P/S forward 4.09
EV/Sales forward 3.16
Short interest 8.80%
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
83%
Hold
17%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
247 247
29% 29%
100%
- Direct Costs 29 29
35% 35%
12%
218 218
28% 28%
88%
- Selling and Administrative Expenses 145 145
25% 25%
58%
- Research and Development Expense 21 21
50% 50%
8%
68 68
228% 228%
27%
- Depreciation and Amortization 19 19
23% 23%
8%
EBIT (Operating Income) EBIT 48 48
170% 170%
20%
Net Profit 40 40
164% 164%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Neutral
Business Wire
10 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
Neutral
Seeking Alpha
20 days ago
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil ...
Neutral
Business Wire
20 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 130
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today